




Review

NMDA Receptor C-Terminal Domain Signalling in Development, Maturity, and Disease

Kirsty Haddow^{1,2,3}, Peter C. Kind^{1,2,3} and Giles E. Hardingham^{1,2,3,*} 

¹ UK Dementia Research Institute, Edinburgh Medical School, University of Edinburgh, Chancellor's Building, Edinburgh EH16 4SB, UK

² Simons Initiative for the Developing Brain, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK

³ Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK

* Correspondence: giles.hardingham@ed.ac.uk

Abstract: The NMDA receptor is a Ca²⁺-permeant glutamate receptor which plays key roles in health and disease. Canonical NMDARs contain two GluN2 subunits, of which 2A and 2B are predominant in the forebrain. Moreover, the relative contribution of 2A vs. 2B is controlled both developmentally and in an activity-dependent manner. The GluN2 subtype influences the biophysical properties of the receptor through difference in their N-terminal extracellular domain and transmembrane regions, but they also have large cytoplasmic Carboxyl (C)-terminal domains (CTDs) which have diverged substantially during evolution. While the CTD identity does not influence NMDAR subunit specific channel properties, it determines the nature of CTD-associated signalling molecules and has been implicated in mediating the control of subunit composition (2A vs. 2B) at the synapse. Historically, much of the research into the differential function of GluN2 CTDs has been conducted in vitro by over-expressing mutant subunits, but more recently, the generation of knock-in (KI) mouse models have allowed CTD function to be probed in vivo and in ex vivo systems without heterologous expression of GluN2 mutants. In some instances, findings involving KI mice have been in disagreement with models that were proposed based on earlier approaches. This review will examine the current research with the aim of addressing these controversies and how methodology may contribute to differences between studies. We will also discuss the outstanding questions regarding the role of GluN2 CTD sequences in regulating NMDAR subunit composition, as well as their relevance to neurodegenerative disease and neurodevelopmental disorders.

Keywords: NMDA receptor; carboxyl (C)-terminal domain (CTD); neurodevelopment; excitotoxicity; neurodegeneration



Citation: Haddow, K.; Kind, P.C.; Hardingham, G.E. NMDA Receptor C-Terminal Domain Signalling in Development, Maturity, and Disease. *Int. J. Mol. Sci.* **2022**, *23*, 11392. <https://doi.org/10.3390/ijms231911392>

Academic Editor: Benoit Roussel

Received: 30 August 2022

Accepted: 23 September 2022

Published: 27 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

N-methyl-d-aspartate receptors (NMDAR) are cation-passing channels gated by the principal excitatory neurotransmitter glutamate which play a crucial role within the central nervous system (CNS) [1,2]. They are permeable to the flow of Ca²⁺, K⁺ and Na⁺, with Ca²⁺ being integral to mediating many of the consequences of NMDAR activity, including the intracellular signalling cascades that govern synaptic modification, activity-dependent development, and neuroprotective signalling. Additionally, inappropriate activation of NMDARs forms an important role in part of the pathological processes underpinning excitotoxic cell death and synaptotoxicity in both acute and chronic neurological disorders [3–5]. NMDARs are heterotetramers consisting of two obligate GluN1 subunits and two GluN2 subunits (GluN2A–D). Expression of GluN2 subunits is regionally localised, with GluN2A and GluN2B being predominant in the forebrain, GluN2C expressed in the cerebellum and GluN2D in the midbrain [1,2]. The identity of the GluN2 subunits contributes to many of the biophysical properties of the receptor, including agonist affinity, channel open

probability, and deactivation kinetics [2,6]. The GluN2 subunits have distinct temporal patterns of expression, compared to GluN2A, GluN2B expression begins earlier in the embryonic brain and maintains high levels of expression during early postnatal development before becoming mainly restricted to the forebrain [7]. After the first two postnatal weeks GluN2A steadily increases, becoming abundant throughout the entire adult CNS. This developmental shift in subunit expression allows for greater GluN2A representation and creates a population of both diheteromeric GluN1₂-GluN2A₂ and GluN1₂-GluN2B₂ NMDARs as well as triheteromeric GluN1₂-GluN2A-GluN2B NMDARs [1,2].

The consequences of NMDAR activation do not rely solely on the influx of ions, but also involve interactions between the NMDAR and several signalling molecules and complexes [8]. The binding sites for these signalling/scaffolding proteins are found within the ~600 amino acid sequence that makes up the GluN2A and GluN2B CTD (CTD^{2A} and CTD^{2B}) [9]. While GluN2 subunits are well conserved in the N-terminal and transmembrane regions, their CTDs have diverged much more, allowing CTD identity to differentially influence the recruitment of signalling complexes and downstream signalling, trafficking, and the functional diversity of NMDAR signalling [10]. However, there are still outstanding questions as to how CTD identity influences key processes such as activity-dependent changes to NMDAR composition, outcome to excitotoxic insult and its role in chronic neurodegenerative states, as well as its contribution to neurodevelopmental disorders. We will attempt to summarise these questions, both where fresh studies are required and also in areas where there are apparent disagreements in the field.

2. The Role of the CTD in Developmental and Activity-Dependent Changes in NMDAR Subunit Composition

The subunit composition of NMDARs changes over the course of development and in response to changes in sensory experience [11–15]. The visual cortex (VC) of rodents has proven to be a particular area of focus in observing activity-dependent changes to subunit composition owing to the ease at which sensory input to the VC can be manipulated. From studies in rats, it has been demonstrated that dark rearing either from birth or during the critical period reduces the levels of GluN2A at the synapse, resulting in a reduction in the ratio of GluN2A to GluN2B (2A:2B ratio) [14,15]. Interestingly, dark reared rats exhibit a rapid increase in GluN2A following 2 h re-exposure to light, suggesting that NMDAR subunit composition, and as such the 2A:2B ratio, can be bidirectionally modified by activity [14,15]. Therefore, the control of this ratio requires a cellular mechanism that can distinguish between GluN2A and GluN2B and selectively incorporate/remove subunits as required within either a developmental or activity-dependent context.

One model for exchanging GluN2B for GluN2A proposes a series of phosphorylation events at a site on the CTD^{2B} [16,17]. NMDAR activity mediates activation of CaMKII α leading to the formation of a trimolecular complex consisting of GluN2B/CaMKII α /Casein kinase 2 (CK2). This association of CK2 with GluN2B leads to phosphorylation of serine-1480 (S1480) on CTD^{2B}. Phosphorylation of S1480 leads to disrupted association of membrane-associated guanylate kinase (MAGUK) proteins at the CTD^{2B} PDZ ligand and a subsequent reduction in phosphorylation at Y1472 within the YEKL endocytic motif, due to the fact that MAGUKs ordinarily recruit the Y1472 kinase Fyn. These events are suggested to lead to lateral diffusion of GluN2B to extrasynaptic sites via a non-PDZ interaction with SAP102 before they are internalised by AP-2 mediated endocytosis, which recognises YEKL when Y1472 is unphosphorylated [16–18]. However, this model was based on experiments involving ectopic overexpression of mutant subunits, potentially altering the relative stoichiometry of CTD^{2B} and CaMKII α or other signalling components that may affect the results. Subsequently, a KI mouse model with a non-functional CaMKII α binding site (GluN2B ^{Δ CaMKII}) was generated that had normal synaptic levels of GluN2A in the adult hippocampus suggested that mutating the CaMKII α binding site may at most delay the developmental subunit shift [19]. Moreover, an independently made second KI mouse with a non-functional CaMKII α binding site (GluN2B ^{Δ CaMKII}) showed that the CaMKII α

site was not required for normal developmental increases in 2A:2B ratio [20]. However, this study only tested the role of CaMKII α site in developmental subunit changes and as such did not rule out the possibility that this site may be important in activity-dependent subunit changes. The same study also utilised a KI mouse model with the CTD of GluN2A replaced by that of GluN2B (GluN2A^{2B(CTR)}) [10] and found that changes to the NMDAR composition in the cortex and hippocampus during development was normal and so do not require GluN2A and GluN2B to have distinct CTDs [20].

Interestingly, while the above study shows that the CTD of GluN2A can be swapped for that of GluN2B with no impairment of GluN2A surface expression, recent studies suggested that in the context of the CTD^{2A}, certain residues may be functionally important for surface expression of GluN2A. Work by Mota Vieira et al. [21] and Yong et al. [22] aimed to functionally characterise the epilepsy-associated variant GluN2A-S1459G and identified S1459 as a CaMKII α phosphorylation site controlled in a development and activity-dependent manner whose mutation impaired interactions with SNX27 and PSD95 as well as GluN2A surface expression when ectopically expressed in cultured neurons. Generation and characterisation of a GluN2A-S1459G KI mouse would further strengthen the case for this phosphorylation event being functionally important for activity-dependent and/or developmental surface expression of GluN2A.

Overall, there are two theories here by which subunit composition shifts during development. The studies which propose the involvement of key CTD phosphorylation events are based predominantly *in vitro* using heterologous expression of mutant receptors, and as such would benefit from *in vivo* studies involving KI mice. The *in vivo* models used thus far have argued against a critical role for the CaMKII α site of CTD^{2B} and subsequent phosphorylation changes proposed by *in vitro* models. If it is the case that phosphorylation events are not crucial, what are the molecular mechanisms that underpin this change? It is an under-appreciated fact that even in the adult mouse the forebrain contains far more GluN2B than GluN2A [23]. The dramatic increase in GluN2A during development, alongside flat or falling levels of GluN2B can at first glance appear like a subunit “switch”—a term that is often used. However, by exploiting KI mice with reciprocal exchange of GluN2 CTDs it was demonstrated that GluN2B levels are around 5-times greater than GluN2A [23]. This means that increased GluN2A insertion is likely to be the main driver of 2A:2B ratio changes since removal of GluN2B on its own would have little effect on the ratio unless very large reductions in GluN2B were involved. Indeed, the 2A:2B ratio has been shown to change developmentally with little or no change to GluN2B levels [20]. This argues against CTD^{2B}-dependent removal of GluN2B being biologically important. The reason why this modest level of GluN2A (even in the adult) has such a strong effect on NMDAR currents (as evidenced by sensitivity to GluN2A antagonists or reduced sensitivity to GluN2B antagonists [24,25]) is that GluN1₂-GluN2A₂ diheteromeric NMDARs have a higher open probability than GluN1₂-GluN2B₂ diheteromeric NMDARs and, moreover, GluN1₂-GluN2A-GluN2B triheteromeric NMDARs more closely resemble GluN1₂-GluN2A₂ NMDARS than GluN1₂-GluN2B₂ NMDARs with regard to their biophysical properties [26]. If removal of GluN2B plays a limited role in the developmental change of 2A:2B ratio and insertion of GluN2A is more important, then what of the role of CTD^{2A}? Since the developmental 2A:2B ratio shift occurs normally in GluN2A^{2B(CTR)} mice where both GluN2B and GluN2A have the same CTD (CTD^{2B}) [20] then CTD^{2A}-dependent events cannot be critical for GluN2A surface delivery. Since GluN2A expression at the mRNA and protein level increases at the same developmental stage as the 2A:2B ratio increases, it could be that this is the only change required, coupled with normal turnover of synaptic proteins.

Experience/activity dependent changes in 2A:2B ratio represent a different situation, studied in most depth in the VC. If sensory deprivation (e.g., dark rearing) causes the 2A:2B ratio to fall, and rise again upon re-exposure to light, then these dynamic changes arguably do require a mechanism for recognising GluN2A-containing NMDARs in instances where they are lost/gained on a timescale incompatible with receptor turnover and changes in

GluN2A gene expression (GluN2A transcription can be controlled by synaptic activity to influence slower-acting changes [27]). Investigations into such ‘recognition’ mechanisms will require further analysis of current KI mouse models as well as new ones, potentially with more targeted mutations in CTD^{2A} or other cytoplasm-facing regions (i.e., the loops that link the membrane spanning domains).

3. GluN2A/2B CTD Mutations Associated with Neurodevelopmental Disorders

Genome sequencing studies have identified over 200 neuropathology associated variants in *GRIN* genes, with a large proportion of these variants being found in *GRIN2A* and *GRIN2B* (Figure 1). As may be expected, most of these variants are found within the highly conserved amino binding domain (ABD) and transmembrane domains (TMD), however, ~20% of these variants occur within the CTD (reviewed by [28]). Mutations are being discovered at a faster rate than the labour-intensive functional characterisation of these CTD variants, but some variants associated with autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy have been studied in detail.




Figure 1. Schematic showing the locations of heterozygous missense, nonsense and frameshift mutations in *GRIN2A* (glutamate receptor ionotropic NMDA 2A) and in *GRIN2B* (NMDA 2B) that have been identified in people with neurodevelopmental disorders. The extreme extracellular amino terminus of these subunits contains allosteric modulation sites. The region between the N terminus and the M1 domain, plus the extracellular loop between the M3 and M4 domains, encode the glutamate-binding domain. The M2 domain features many side chains that point towards the receptor channel pore and dictate ion permeability. Finally, the long cytoplasmic carboxy-terminal domain is involved in receptor targeting and coupling to downstream signalling complexes. Figure based on refs. [21,29–52].

Liu et al. [41] characterised an autism associated GluN2B mutant occurring in the CTD of GluN2B (S1415L human, S1413L rodent). Rat hippocampal neurons transfected with mutant GluN2B showed a 30% reduction in receptor surface expression compared to GluN2B WT. In addition, GluN2B S1413L-expressing neurons also showed a reduction in spine density. From this it would appear that the CTD^{2B} plays an important role in the trafficking of GluN2B to the synaptic membrane which when impaired may lead to a reduction in dendritic spines. For CTD^{2B} mutations in which trafficking deficits and morphological changes are observed, there is some question as to whether differences in morphology occur as a result of the loss of intracellular signalling linked to the CTD^{2B} or whether these changes are simply a consequence of altered NMDAR at the synapse. Using chimeric mouse models with reciprocally swapped CTDs, Keith et al. [53] found that replacing CTD^{2A} for CTD^{2B} in GluN2A results in longer total dendritic path, average apical length, and total basal length relative to WT mice. They observed no difference between WT and a model replacing CTD^{2B} for CTD^{2A} in GluN2B, and importantly, replacing the ABD or TMD of GluN2A for that of GluN2B had no effect on morphology. As such, these results indicate that CTD^{2B}-specific intracellular signalling pathways are a key regulator in dendritic morphology, raising the possibility that deficits in CTD^{2B} signalling may contribute to altered development in ASD/ID. Future studies probing the potential role of the S1423L variant on dendritic complexity and spine morphology will help to shed light on the role of CTD^{2B} signalling in ASD/ID neurodevelopment [41].

Mutations in *GRIN2A* are commonly associated with developmental delay and epileptic phenotypes [38,54]. While these mutations predominantly occur in the ABD or TMD resulting in functional changes to the subunits, a number of epilepsy-associated variants have also been identified within the CTD^{2A} [21,38,39]. In addition to the NMDAR mediated Ca²⁺ influx that is required for the induction of plasticity, there is also some evidence to suggest that GluN2 CTD identity influences synaptic plasticity induced by different patterns of activity [10]. Therefore, mutations that either affect trafficking of the GluN2A subunit or that alter key interaction sites have the potential to impair synaptic plasticity. However, seemingly counterintuitively, mutations in the CTD^{2A} that enhance trafficking also negatively impact plasticity. Li et al. [40] recently characterised a rare ID associated variant in the GluN2A subunit. The mutation, K879R, was found to occur within an endoplasmic retention signal motif and resulted in enhanced cell surface expression. The increased expression of GluN2A led to deficits in synaptic transmission both in GluN2A_K879R mouse hippocampal CA1 neurons and in K879R KI mice. Additionally, KI mice exhibited impairments in the induction of LTP and LTD as well as deficits in learning and memory. This suggests the importance of a carefully controlled balance of GluN2A levels, or 2A:2B ratio. It also suggests that any therapeutic approaches should avoid the potentially severe impacts of over-correcting GluN2A deficits.

As mentioned previously different GluN2 subunits influence the biophysical properties of NMDARs. The relatively faster deactivation kinetics of GluN2A-containing NMDARs relative to GluN1₂-GluN2B₂ NMDARs allows for GluN2 subunit composition to modify Ca²⁺ influx in response to synaptic input and as such the downstream consequences such as the induction of LTP vs. LTD. Furthermore, it has been observed that altering synaptic activity leads to changes in neural function that influences the subsequent induction of synaptic plasticity—so called “metaplasticity” (reviewed thoroughly elsewhere [55,56]). As such, control of the 2A:2B ratio in response to synaptic input has been proposed as one of the mechanisms by which neuronal activity is kept within a functional range in response to changing levels of activity. Considering the potential role of NMDAR subunit composition in homeostatic regulation of activity, it could be suggested that mutations in *GRIN2A* promote epileptic phenotypes through either a reduction or loss of function of the GluN2A subunit itself, e.g., caused by mutations that affect agonist binding and channel properties, or through a reduction in subunit expression at the synapse. The result of any of these mutations would lead to reduction in GluN2A activity, thereby leading to an impaired homeostatic ability of circuits and the facilitation of hyper-excitability. However,

it should also be noted that a loss of excitatory drive from inhibitory interneurons and subsequent disinhibition as a result of a loss of GluN2A function may also contribute to hyper-excitability. Indeed, it was recently shown that enhancing GluN2A activity in both excitatory and inhibitory interneurons with the use of the positive allosteric modulator (PAM) GNE-0723 reduced epileptiform activity in mouse models of Alzheimer's disease (AD) and Dravet syndrome [57]. Overall, it appears that the 2A:2B ratio is important in mediating seizure susceptibility. Specifically, a decrease in this ratio favours increased seizure susceptibility. In the hippocampus both a decrease in GluN2A expression [58] and upregulation of GluN2B [59] have been implicated in contributing to seizure pathogenesis. In addition, selective blockade of GluN2B has been shown to reduce seizure susceptibility [60,61] and dextromethorphan induced convulsive behaviours [62]. However, it remains unclear whether the beneficial effect of modifying the relative activity of GluN2A/2B is solely the result of restoring homeostatic balance or whether subunit specific signalling pathways are also involved. Crucially, there is currently no evidence to suggest that CTD-dependent effects mediate the subunit-specific effect on seizure pathogenesis.

As advances in the technology make it easier to generate genetic models for *GRIN2A* variants, the challenge shifts to assessing the face validity of these models. For example, a recent study generated a KI mouse for a de novo heterozygous *GRIN2A* variant identified in a patient with ID and epileptic encephalopathy (S644G) [63]. Mice homozygous for S644G unexpectedly died of a lethal seizure during the third postnatal week, but heterozygous mice had a normal lifespan and exhibited neither behavioural seizures nor epileptiform activity. They did, however, exhibit both an increased seizure susceptibility and an increased seizure resistance in response to different electroconvulsive threshold testing, highlighting the biological complexity of *GRIN2A* involvement in epileptic encephalopathy [63]. Therefore, while mouse models provide a valuable opportunity to probe the cellular and circuit level consequences of *GRIN2A* mutations, care should be taken when translating findings across species.

Overall, understanding the molecular consequences of *GRIN2A* and *GRIN2B* mutations may provide an opportunity for targeted therapeutic strategies. Indeed, several preclinical pharmacological studies have highlighted the potential for the use of both negative allosteric modulators (NAMs) and PAMs in treating gain of function and loss of function *GRIN* variants, respectively [64–67]. However, it is important to consider that allosteric modulators may be influenced by intracellular factors such as the phosphorylation, ubiquitination and palmitoylation states of CTDs. This was highlighted in a recent study in which it was demonstrated that GluN2 deletions robustly altered the activity of both PAMs and NAMs, likewise, agents altering phosphorylation state and intracellular Ca^{2+} levels were also observed to produce receptor-specific and compound specific changes to PAM activity [68]. Therefore, further studies investigating the metabotropic influence of CTDs on the activity of allosteric modulator will be a crucial step in paving the way to developing appropriate treatment strategies for aberrant NMDAR activity.

4. A Critical Role for CTD Interactions in Acute Excitotoxicity

It has been observed that when neurons are subject to sustained elevated glutamate, cell death occurs [69]. In the 1980s, it was observed that excessive Ca^{2+} influx through NMDARs is a key mediator in the neuronal death observed in response to glutamate exposure [70]. Moreover, Tymianski et al. [71] demonstrated that the route of entry, specifically via NMDARs, was more important than overall Ca^{2+} load. This finding was later expanded on by Sattler et al. [72] who confirmed that lower Ca^{2+} influxes through NMDARs produced greater lethality when compared to high Ca^{2+} influx via other Ca^{2+} permeant channels. As such, these findings suggest that there is either functional and/or physical coupling of NMDARs to Ca^{2+} -responsive mediators of cell death signalling. Of note however, physiological patterns of synaptic NMDAR activity are known to be protective leading to the classic bell-shaped curve model for neuronal response to NMDAR activity [73,74]. However, beyond simple level of activity mattering, the question remained

as to whether NMDAR subunit compositional diversity influences the consequence of NMDAR activation, particularly via the divergent CTDs of GluN2A and GluN2B. GluN2A and GluN2B containing NMDARs are both capable of mediating excitotoxicity; however, there is evidence to suggest that CTD identity may influence the tendency to couple to either pro-death or pro-survival signalling pathways (Figure 2). Of note, there is also emerging evidence for the presence of ion flux independent excitotoxicity. Recently, it has been reported that NMDARs form a signalling complex with Src kinase and Panx1 in response to NMDAR ligand binding without activation of their ion conduction pore [75]. Furthermore, disruption of this signalling complex was observed to be neuroprotective both in vitro and in vivo [75]. This is somewhat controversial as it disagrees with many of the existing studies regarding the ion flux dependent nature of excitotoxicity. Regardless of this, as ion flux-independent mechanisms appear to involve NMDAR recruitment of signalling complexes it would be of interest to establish the role of GluN2 CTD specific interactions in this proposed mechanism for excitotoxicity.




Figure 2. Schematic showing some of the proposed mechanisms underpinning CTD specific and location specific downstream consequences of acute excitotoxicity. At synaptic sites activation of GluN2A containing NMDARs (green) promotes expression of CREB and pro-survival genes and inhibits the PTEN pathway shut-off of pro-survival genes. Synaptic GluN2B containing NMDARs (yellow) may mediate pro-survival or pro-death signalling depending on the level of glutamate. When faced with excitotoxic glutamate levels preferential GluN2B/PSD95/nNOS coupling promotes NO mediated shut off of CREB, oxidative stress and subsequent cell death. Direct coupling of CTD^{2B} to mitochondrial proteins may also facilitate Ca²⁺ overload and mitochondrial dysfunction (potential but unconfirmed pathway; ?). At extrasynaptic sites physical and functional coupling of both CTD^{2A} and CTD^{2B} with TRPM2 and 4 may result in enhanced extrasynaptic NMDAR activity to promote cell death. Therefore, it is possible that a hierarchy exists in which a combination of both composition and location determines the downstream consequences of NMDARs.

Previously, it has been demonstrated that GluN2A containing NMDARs are linked to intracellular signalling cascades that promote the activation of neuroprotective transcription factors such as cAMP response element-binding protein (CREB) and a reduction in the expression of genes such as phosphatase and tensin homolog (PTEN), which is involved in pathological processes associated with neuronal injury [76,77]. In contrast, GluN2B containing NMDARs have been shown to couple with signalling pathways that suppress CREB-dependent survival pathways [78]. However, it is important to note that the CTD^{2B} can also mediate signalling that is neuroprotective. For instance, the GluN2B-PTEN signalling pathway has also been shown to enhance the expression of Dysfunction of PTEN-induced kinase 1 (PINK1) which potentiates GluN2A and its pro-survival signalling pathways [79].

In addition to the preferential recruitment of pro-death vs. pro-survival signalling mediated by GluN2 CTD identity, there is also evidence to suggest that location rather than composition alone is a key determinant in whether pro-death signalling pathways are preferentially activated. For instance, it has been demonstrated that extrasynaptic NMDARs preferentially promote CREB inactivation and mitochondrial dysfunction whereas activation of their synaptic counterparts does not induce mitochondrial dysfunction and instead induces protective CREB-dependent gene expression in a nuclear Ca²⁺-dependent manner [3,78,80–85]. Interestingly, this distinction between extrasynaptic and synaptic NMDARs persists during developmental time points where GluN2B is predominant, suggesting that location is a significant factor in determining the downstream consequences of NMDAR activation [86,87]. Overall, a combination of both identity and location are likely to be important in determining the downstream consequences of NMDAR activation, although it will be of benefit in the future to validate key findings in human neuronal models of excitotoxicity including strategies to alter synaptic-extrasynaptic balance [88,89].

4.1. GluN2B Mediated Excitotoxicity through PSD95-nNOS Pathway

Using the novel GluN2A^{2B(CTR)} and GluN2B^{2A(CTR)} KI models Martel et al. [90] observed that GluN2A^{2B(CTR)} mice showed enhanced NMDA induced excitotoxicity compared to WT. Interestingly, it was also found that GluN2B^{2A(CTR)} mice showed a reduction in the vulnerability of forebrain neurones to excitotoxic levels of Ca²⁺ influx through the NMDAR both in vivo and in vitro. Thereby suggesting that GluN2B may preferentially couple to pro-death signalling pathways. Indeed, when examining the mechanistic basis for GluN2 CTD subtype specific differences, it was observed that GluN2B^{2A(CTR)} mice exhibited both a prolonged phosphorylation of CREB and a reduction in coupling to nitric oxide (NO) production in response to excitotoxic conditions. NO can suppress CREB phosphorylation at high levels [91–93], it is produced when NMDAR-mediated Ca²⁺ influx activates nitric oxide synthase, which is recruited to the NMDAR signalling complex via PSD95 association with CTD^{2B} [91]. Therefore, the findings by Martel et al. [90] suggest that CTD^{2B} may preferentially couple to this PSD95/nNOS pathway to promote cell death.

In light of the failure of conventional NMDAR antagonists in stroke trials [94], there is a need for more finely tuned interventions that can target specific pro-death signalling interactions without impairing physiological functioning of NMDARs. The generation of a cell-permeable mimetic peptide of the GluN2B-PSD95 PDZ domain, known as NA-1 (also known as TAT-NR2B_{9C}), that was designed to reduce coupling of nNOS to GluN2B via PSD95 produced a lot of optimism owing to its neuroprotective effects in stroke models in rodents and monkeys [91,95]. However, following on from a successful phase II trial for safety and efficacy for iatrogenic micro-strokes during cerebral aneurysm repair, it has since failed human clinical [96,97]. However, an exploratory analysis did reveal a potential drug–drug interaction between NA-1 and the usual care thrombolytic alteplase that may nullify the treatment effect of the former [96]. This observation requires further investigation, but it leaves some hope for the therapeutic benefit of NA-1.

4.2. The Role of Extrasynaptic Specific Physical and Functional Coupling in Excitotoxicity

It has been suggested that extrasynaptic specific protein(s) coupling to the NMDAR promotes pro-death signalling pathways. Yan et al. [98] identified a physical interaction between extrasynaptic NMDARs and TRPM4 that they demonstrated as being vital in facilitating excitotoxicity. The use of small molecule NMDAR/TRPM4 interaction interface inhibitors was observed to provide robust protection against cell death *in vivo* and *in vitro* as well as inhibiting excitotoxicity-mediated transcriptional changes and mitochondrial dysfunction. Since proteomic data from mouse and human cortex and hippocampus indicates that TRPM4 is absent at the synapse, this study proposes that NMDAR-TRPM4 interactions may offer some explanation as to the differences in the response of synaptic vs. extrasynaptic NMDARs during increased Ca^{2+} load. Similarly, it has also been observed that TRPM2 ion channels functionally couple with extrasynaptic NMDARs to enhance excitotoxicity in mouse models of ischaemic brain injury [99]. *Trpm2* knock-out (KO) mice exhibited a reduced infarct volume and an improved neurological performance compared to WT mice following middle cerebral artery occlusion (MCAO), which is in agreement with observations made previously in these KOs [100]. Furthermore, it was found that Protein kinase C gamma ($\text{PKC}\gamma$) was readily coimmunoprecipitated with anti-TRPM2 in brain lysates and that this interaction was increased following MCAO [99]. Considering that $\text{PKC}\gamma$ has been shown to regulate NMDAR surface trafficking [101,102], this study suggests that TRPM2-NMDAR interactions may exacerbate excitotoxicity by increasing the surface expression of extrasynaptic NMDARs, enhancing extrasynaptic NMDAR activity thereby promoting cell death.

Both studies observe a reduction in cell death following uncoupling of their respective TRPM channels, suggesting that uncoupling of either would be sufficient to reduce cell death. This implies that both TRPM2 and 4 are required for extrasynaptic mediated cell death, potentially with one interaction mediating increased levels of extrasynaptic NMDARs and the other mediating location specific potentiation of extrasynaptic NMDAR responses. Interestingly, both studies demonstrated that TRPM2 and TRPM4 interaction sites are present on both CTD^{2A} and CTD^{2B} . This coupled with the observation by Martel et al. [90] that swapping the CTD^{2B} with that of CTD^{2A} reduces but does not abolish excitotoxicity, further suggests that CTD identity may be an additive factor to the influence of location (synaptic vs. extrasynaptic) on excitotoxicity.

4.3. DAPK1 Interactions at CTD^{2B} Do Not Mediate Excitotoxic Cell Death

While earlier work by Tu et al. [103] suggested a role for death-associated protein kinase 1 (DAPK1) mediated phosphorylation of CTD^{2B} Ser-1303 (s1303) in the pro-death signalling that occurs during excitotoxicity, subsequent studies have failed to reproduce these findings. Indeed, it has since been observed that excitotoxicity persists even in the absence of DAPK1, *in vivo* and *in vitro*, and moreover, s1303 phosphorylation does not differ between neuronal cultures from $\text{DAPK1}^{-/-}$ and $\text{DAPK1}^{+/+}$ mice during either basal or excitotoxic conditions [104]. In agreement with this, another study using GST-fusion proteins with the CTD of GluN2B as a phosphorylation substrate for $\text{CaMKII}\alpha$ and DAPK1 found that phosphorylation of s1303 is four orders of magnitude weaker by DAPK1 compared to $\text{CaMKII}\alpha$ and therefore s1303 is a poor substrate for DAPK1 phosphorylation [105] (Table 1). Based on these findings, CTD^{2B} - $\text{CaMKII}\alpha$ interaction would appear to be a better candidate mechanism in CTD^{2B} mediated excitotoxic cell death. If this were to be the case, one would predict that mice such as the $\text{GluN2B}^{\Delta\text{CaMKII}}$ mouse, which possess a mutated $\text{CaMKII}\alpha$ binding site, would exhibit a reduction in cell death when compared to their WT counterparts. In agreement with this, Buonarati et al. [106] demonstrated that ΔCaMKII mice (L1298A/R1300Q) exhibit reduced hippocampal cell death following an *in vivo* cardiac arrest/cardiopulmonary resuscitation model (CA/CPR). Crucially, while the ΔCaMKII mutation abolished $\text{CaMKII}\alpha$ binding at CTD^{2B} , no effect was observed for DAPK1. Therefore, based on the current evidence, it would appear that CTD^{2B} -DAPK1 binding is not a key mediator of excitotoxic cell death.

Table 1. Summary of findings from DAPK1 studies.

Model	Treatment	Findings	Study
HEK293	Coexpression of GluN1/GluN2B and constitutively active DAPK1	↑ GluN1/GluN2B peak amplitude of receptor currents ↑ S1303 phosphorylation	[103]
DAPK1 ^{+/+} cortical neurons	OGD	↑ S1303 phosphorylation ↑ amplitude of extrasynaptic NMDA mediated currents and Ca ²⁺ transients	[103]
DAPK1 ^{+/+} cortical neurons	Bath application of NMDA (20 μM and 50 μM) and OGD	No change in s1303 phosphorylation	[104]
DAPK1 ^{-/-} cortical neurons	OGD	No change in s1301 phosphorylation	[103]
DAPK1 ^{-/-} in vivo	MCAO	↓ infarct volume as measured by TTC staining	[103]
DAPK1 ^{-/-} in vivo	MCAO	No change to infarct volume as measured by H-E staining	[104]
DAPK1 ^{+/+} in vivo	CA/CPR	No change in s1303 phosphorylation	[105]

Note: an up arrow indicates an increase; a down arrow indicates a reduction or decrease.

When looking for an explanation for contradictory findings between the initial study and subsequent studies, attention falls to the methodology. Tu et al. [103] demonstrated a neuroprotective effect by using a peptide mimetic of S1303, Tat-NR2B_{CT}, to uncouple CTD^{2B}-DAPK1 interaction. However, McQueen et al. [104] found that the Tat-NR2B_{CT} acts as a potent NMDAR antagonist and hypothesised that this was due to the peptide binding near the Mg²⁺ site. In agreement with this, they found that Tat-NR2B_{CT} acted as an open channel blocker. Therefore, this may account for the neuroprotective qualities previously observed. In addition, the study by Tu et al. [103] also used a 2,3,5-Triphenyl tetrazolium chloride (TTC) stain as a measure for brain infarct volume. TTC is a water-soluble dye that is reduced by mitochondrial enzymes, as such it reflects metabolic consequences of ischaemia that may occur independently of cell death [107,108]. Therefore, the reduced infarct volumes observed in response to DAPK1 deletion may reflect reduced metabolic damage rather than cell death. In agreement with this, it was concluded by a recent meta-analysis of the literature that while inhibition of DAPK1 does reduce the gradual loss to neuronal function and structural integrity (i.e., degeneration) following cerebral hypoxic ischaemia, it does not alter the immediate cell death observed in response to ischaemia [109]. Therefore, while DAPK1 may play a role in the mechanisms that lead to the impairment of neuronal function following ischaemia, other pathways mediate ischaemic cell death.

4.4. Role of GluN2A and GluN2B in Tissue-Type Plasminogen Activator Mediated Neuroprotection

Recent evidence also suggests a role for subunit identity in differentially mediating the downstream consequences of non-conventional NMDAR binding proteins. Tissue-type plasminogen activator (tPA) is a serine protease involved in the breakdown of blood clots, as such, it is used in the early stage treatment of ischaemic stroke in order to aid the breakdown of clots and restore blood flow. Previously it has been demonstrated that tPA interacts with the ABD of GluN1 to promote a selective increase in the surface dynamics of extrasynaptic NMDARs resulting in the promotion of NMDAR-mediated calcium influx and excitotoxicity [110]. However, tPA interaction with GluN2A containing NMDAR has been shown to promote neuroprotective signalling, an effect which is ameliorated by blocking either GluN2A or synaptic NMDARs [111,112]. Based on the previous assumption that GluN2B is enriched at extrasynaptic sites, this finding seemed to indicate differential roles for tPA interaction with GluN2A and GluN2B in mediating neuroprotection and pro-death signalling, respectively. However, current evidence suggests that GluN2 composition may not be drastically different between synaptic and extrasynaptic sites [90,113–115], again suggesting that the main driving force in the loss of neuroprotection is the activation of

extrasynaptic-specific pathways, with subunit composition possibly providing an additive effect. Interestingly, a recent study demonstrated that the two-chain form of tPA (tc-tPA) recruits GluN2B containing NMDARs in a MET receptor tyrosine kinase dependent manner to drive the down regulation of extrasynaptic GluN2B and promote neuroprotection [116]. It is therefore possible that the downstream consequences of tPA interaction with NMDARs depend on a combination of factors including NMDAR location, composition, and the form of tPA involved (single vs. two chain form). Of note, tc-tPA was also observed to reduce CTD^{2B} phosphorylation [116], as such it would be of interest to probe the role of the CTD in tPA mediated neuroprotection using both Δ CaMKII and CTD KI mouse models.

5. Role of CTD^{2B} in Alzheimer's Disease?

The role of CTD signalling in chronic neurodegenerative disease is an area of particular interest, especially with regard to AD. In the AD brain, as the disease progresses, mitochondrial dysfunction and subsequent bioenergetic failure, glutamate release from inflammatory cells and astrocytes, and a reduction in astrocytic glutamate transporter expression may all facilitate the loss of glutamate homeostasis, leading to a rise in ambient glutamate [117–119]. As opposed to the rapid cell death that is observed during acute excitotoxicity, this chronic increase in ambient glutamate may act as a low-level, gradual excitotoxic insult that progressively impairs synaptic integrity and eventually leads to cell death [118]. Furthermore, the tonic activation of extrasynaptic NMDARs exacerbates the situation by promoting amyloid-precursor protein (APP) processing [120,121]. Given that there is evidence to suggest that CTD identity influences coupling to pro-death vs. pro-survival signalling in acute excitotoxicity, it is important to question whether CTD identity similarly influences signalling pathways in neurodegeneration.

5.1. Role of CTD^{2B} in Ionotropic and Metabotropic Dependent Pathways in AD

The downstream consequences of NMDAR activation have been robustly demonstrated to rely on Ca²⁺ influx via NMDARs, either through increasing intracellular Ca²⁺ or by activation of Ca²⁺ dependent enzymes associated with NMDAR CTDs. However, in recent years there has been some evidence to suggest that at least some consequences of NMDAR activation may be mediated by ion-flux independent metabotropic pathways (reviewed by [122]). So far, it has been demonstrated that ion-independent conformational changes of the CTD alter protein binding in response to NMDA activation in both synaptic plasticity and A β pathology [123–126]. In the context of AD, CTD^{2B} has been implicated as being important in both enhanced ionotropic-dependent pro-death pathways as well as A β dependent metabotropic pathways [124].

Using a mouse model expressing a truncated form of tau, Δ Tau⁷⁴, Ittner et al. [127] demonstrated that tau interaction with the SRC kinase Fyn is crucial in determining its localisation at the PSD. Furthermore, they found that localisation of Fyn at the PSD via its interactions with tau led to phosphorylation of the Y1472 site on the CTD^{2B} resulting in a strengthening of the interactions between CTD^{2B} and PSD95. As discussed previously, the interaction between CTD^{2B} and PSD95 is thought to play a crucial role in pro-death signalling, and as such Ittner et al. [127] suggest that tau-Fyn phosphorylation of CTD^{2B} contributes to tau pathology by increasing stability of the NMDARs at the PSD and coupling to excitotoxic downstream signalling pathways (Figure 3A).

In contrast to the findings of Ittner et al. [127], it has also been demonstrated that CTD^{2B}-PSD95 interaction may be protective in Amyloid beta (A β) pathology. By using organotypic hippocampal slices infected with viral vector containing CT100 (beta-secretase cleavage product of APP) and PSD95 it has been observed that increased interaction of CTD^{2B} and PSD95 may stabilise NMDARs resulting in NMDAR induced potentiation that acts to compensate for A β induced depression. GluA1 KO mice fail to exhibit potentiation in PSD95 overexpression slices, thereby demonstrating that PSD95 mediated potentiation requires GluA1. On the other hand, expressing CT100 was still able to mediate depression, however, this depression was abolished by coexpressing PSD95. Taken together, this

suggests that PSD95 overexpression blocks A β induced depression independently of its ability to potentiate synaptic transmission [124]. From this it was hypothesised that the protective effect of PSD95 may be achieved by constraining the conformation of the CTD such that signalling pathways that promote depression are blocked. Using FRET-FLIM assay, they demonstrated that over expression of PSD95 prevents the reduced FRET efficiency observed in the presence of CT100, and interestingly, it was also observed that overexpression of PSD95 blocked the loss of FRET interaction between GluN1 and protein phosphatase 1 (PP1) [124]. Therefore, they propose a mechanism by which over-expression or increased endogenous expression of PSD95 stabilises CTD^{2B} conformation to prevent A β interaction with PPI that promotes synaptic weakening (Figure 3B).




Figure 3. Schematic showing the contrasting mechanisms proposed for the CTD^{2B} in tau and A β pathology. (A) Interaction between tau and Fyn mediates Fyn localisation to the PSD where it phosphorylates Y1472. Phosphorylation of Y1472 leads to stronger GluN2B/PSD95 coupling resulting in increased GluN2B containing NMDAR stability at the PSD and recruitment of pro-death signalling pathways. (B) Enhanced GluN2B/PSD95 coupling either by overexpression of PSD95 or enhancing endogenous expression stabilises the conformation of the CTD^{2B}, preventing A β interactions with PPI that result in depression and subsequent weakening of synapses.

These two studies present two different potential roles for CTD^{2B}-PSD95 interactions in the pathology of AD, opposing in nature. The evidence of both a beneficial and detrimental role for CTD^{2B}-PSD95 in AD raises many questions, for instance, is one mechanism dominant over the other? That is to say, would the beneficial effect of uncoupling CTD^{2B}-PSD95 on tau pathology produce an overall therapeutic effect despite possibly exacerbating A β pathology? Another question is whether there are specific time points of the disease pathology in which targeting CTD^{2B}-PSD95 interactions would be most beneficial? For instance, while enhancing CTD^{2B}-PSD95 interactions might provide some therapeutic effect

in early stages of the disease, it may prove detrimental when there is a loss of glutamate homeostasis, potentially contributing to local synaptotoxicity or neuronal loss.

5.2. Implications for Astrocytic NMDA Subunits in AD?

As alluded to previously, AD possesses a complex pathology that involves dysfunction of both neurons and glia. Moreover, as NMDARs have also been shown to be expressed in astrocytes [128,129] this yields the possibility that NMDAR activation may contribute to pathological changes observed to astrocytic function. For instance, GluN2C is expressed by astrocytes in the majority of the telencephalon [130,131] and GluN2A has been observed to be expressed in hippocampal astrocytes [132]. Moreover, it was recently demonstrated that astrocytic GluN2A expression is increased in post-mortem brain tissue taken from AD patients [132]. While the exact role of astrocytic NMDARs in disease pathology remains unclear, there is some evidence to suggest that these receptors can mediate both protective and pathological processes. Previous *in vitro* studies have found that exposure of neuron astrocyte co-cultures to NMDA promotes an increase in the antioxidant capacity of neurons [133] whereas overexposure to NMDA disrupts astrocytic homeostatic function [134,135]. This yields the interesting possibility that the level of astrocytic NMDAR expression and/or subunit composition and CTD identity dependent signalling may contribute to the pathological processes observed in AD and other neurodegenerative disorders in which glial dysfunction is a component. As such, further research is needed to uncover the mechanisms by which astrocytic NMDAR activation may contribute to disease pathology.

6. Contribution of CTD^{2A} and CTD^{2B} in Other Disease Pathologies?

As well as AD, there is also evidence to suggest that GluN2 CTD identity contributes to pathology in a wide range of diseases. In the case of Parkinson's disease (PD), it has been observed that rat models mimicking both early and advanced stage PD exhibit increased synaptic GluN2A, resulting in an increased 2A:2B ratio and plasticity deficits [136,137]. Interestingly, the use of permeable protein mimetics to modulate CTD^{2A} MAGUK binding was found to restore synaptic plasticity and reduce motor impairments [136]. This suggests that CTD^{2A} may serve as a potential therapeutic target in PD, however, as dopaminergic denervation appears to be important in driving subunit compositional changes it would also be of interest to establish the mechanisms by which this occurs.

GluN2 subunit composition has also been implicated in Huntington's disease (HD). Of note, it has been observed across multiple species that the striatum exhibits higher levels of GluN2B relative to other brain regions [138–141]. Moreover, an increase in GluN2B at extrasynaptic sites on medium-sized spiny striatal neurons has been observed to contribute to phenotype onset [142,143] in a model of HD where synaptic/extrasynaptic NMDAR balance influences the inclusion and toxicity of mutant huntingtin [144]. This may suggest that both GluN2 subunit identity and location influence the progression of HD pathology, however, further investigation is required to establish the contribution of CTD^{2B} mediated signalling.

Impaired NMDAR-mediated neurotransmission has been proposed as one of the contributing factors in schizophrenia (SZ) pathology, owing to the observation that psychomimetic compounds can transiently replicate SZ symptomology by blocking NMDAR neurotransmission [145,146]. Genetic evidence also points to a role for disrupted NMDAR signalling in SZ. For instance, *GRIN2A* has been implicated as a risk gene for SZ by a recent genome wide association study [147]. In addition, exome sequencing has revealed several *de novo* SZ associated mutation in both the *GRIN2A* and *GRIN2B* genes, several of which occur in the CTD [42,49]. However, it remains to be seen whether these *de novo* CTD mutations are causative in SZ. If they do indeed contribute to the pathogenesis of SZ, the question then becomes by what means? Do these mutants disrupt key CTD dependent signalling pathways or do they simply impair trafficking and therefore synaptic NMDAR content. Robust characterisation of these variants will be required to address these key questions.

7. Concluding Remarks

Studies are starting to shed light on the role of NMDAR CTDs in both neurodevelopment, acute excitotoxicity, and neurodegeneration. However, despite this, many questions remain unanswered. For instance, while evidence suggests that CTDs are not required for developmental NMDAR compositional changes, the role of CTD sequences in activity-dependent compositional changes remains to be ascertained. Future work using both currently available KI mouse models and KO models of putatively important phosphorylation sites is needed to shed light on the vital mechanisms underpinning this process. Additionally, if the CTD is identified as important in this mechanism then the next task would be to identify how CTD sequences control subunit removal and insertion at the synapse, and whether this process is dependent on phosphorylation events, CTD specific signalling cascades, or whether stability in response to changing activity is different between subunits owing to the recruitment of different protein complexes by distinct CTDs. A better understanding of the mechanisms involved in activity-dependent changes will set the groundwork for identifying how these processes may be aberrant in neurodevelopmental disorders. In the meantime, it would also be beneficial to functionally characterise some of the many CTD variants that have already been identified in ASD, ID and epilepsy patients.

While this review mainly focuses on GluN2A and GluN2B CTDs, it is important to note that there is also evidence to suggest a role for the influence of GluN2C and GluN2D in neuronal survival and cell death (reviewed by [148]). Both in vitro and In vivo evidence suggests a critical role for GluN2D in NMDA-induced excitotoxicity [149–151]. This suggests that GluN2D, much like GluN2B, may preferentially couple to pro-death signalling pathways to mediate cell death in brain regions where GluN2D is expressed. Therefore, it would be of great interest to establish the involvement, if any, of the GluN2D CTD in GluN2D mediated excitotoxicity. Finally, as a goal of understanding the role of GluN2 CTDs in pathophysiology is to identify potential therapeutic targets, it is important to understand how post translational modification of the CTD influences the efficacy of therapeutic drugs. It has already been demonstrated that phosphorylation and palmitoylation state of the CTD can influence the sensitivity of NMDARs to pharmacological intervention [68,152]. Therefore, establishing how particular disease states may influence post translational modification of the CTD will be important in developing optimal therapeutic strategies.

Funding: The GEH laboratory is supported by UK Dementia Research Institute founding funders UK Medical Research Council, Alzheimer’s Research UK and Alzheimer’s Society, as well as the Simons Initiative for the Developing Brain. The PCK laboratory is supported by the Simons Foundation via the Simons Initiative for the Developing Brain.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank Katie Marwick for preparing the original version of Figure 1. Figures were created with BioRender.com.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Paoletti, P.; Bellone, C.; Zhou, Q. NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease. *Nat. Rev. Neurosci.* **2013**, *14*, 383–400. [[CrossRef](#)]
2. Wyllie, D.J.; Livesey, M.R.; Hardingham, G.E. Influence of GluN2 subunit identity on NMDA receptor function. *Neuropharmacology* **2013**, *74*, 4–17. [[CrossRef](#)]
3. Hardingham, G.E.; Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. *Nat. Rev. Neurosci.* **2010**, *11*, 682–696. [[CrossRef](#)]
4. Parsons, M.P.; Raymond, L.A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. *Neuron* **2014**, *82*, 279–293. [[CrossRef](#)]

5. Tymianski, M. Emerging mechanisms of disrupted cellular signaling in brain ischemia. *Nat. Neurosci.* **2011**, *14*, 1369–1373. [[CrossRef](#)]
6. Vicini, S.; Wang, J.F.; Li, J.H.; Zhu, W.J.; Wang, Y.H.; Luo, J.H.; Wolfe, B.B.; Grayson, D.R. Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. *J. Neurophysiol.* **1998**, *79*, 555–566. [[CrossRef](#)]
7. Monyer, H.; Burnashev, N.; Laurie, D.J.; Sakmann, B.; Seeburg, P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. *Neuron* **1994**, *12*, 529–540. [[CrossRef](#)]
8. Collins, M.O.; Grant, S.G. Supramolecular signalling complexes in the nervous system. *Subcell. Biochem.* **2007**, *43*, 185–207.
9. Ryan, T.J.; Emes, R.D.; Grant, S.G.; Komiyama, N.H. Evolution of NMDA receptor cytoplasmic interaction domains: Implications for organisation of synaptic signalling complexes. *BMC Neurosci.* **2008**, *9*, 6. [[CrossRef](#)]
10. Ryan, T.J.; Kopanitsa, M.V.; Indersmitten, T.; Nithianantharajah, J.; Afinowi, N.O.; Pettit, C.; Stanford, L.E.; Sprengel, R.; Saksida, L.M.; Bussey, T.J.; et al. Evolution of GluN2A/B cytoplasmic domains diversified vertebrate synaptic plasticity and behavior. *Nat. Neurosci.* **2013**, *16*, 25–32. [[CrossRef](#)]
11. Chen, W.S.; Bear, M.F. Activity-dependent regulation of NR2B translation contributes to metaplasticity in mouse visual cortex. *Neuropharmacology* **2007**, *52*, 200–214. [[CrossRef](#)] [[PubMed](#)]
12. Philpot, B.D.; Espinosa, J.S.; Bear, M.F. Evidence for altered NMDA receptor function as a basis for metaplasticity in visual cortex. *J. Neurosci.* **2003**, *23*, 5583–5588. [[CrossRef](#)] [[PubMed](#)]
13. Philpot, B.D.; Weisberg, M.P.; Ramos, M.S.; Sawtell, N.B.; Tang, Y.P.; Tsien, J.Z.; Bear, M.F. Effect of transgenic overexpression of NR2B on NMDA receptor function and synaptic plasticity in visual cortex. *Neuropharmacology* **2001**, *41*, 762–770. [[CrossRef](#)]
14. Quinlan, E.M.; Olstein, D.H.; Bear, M.F. Bidirectional, experience-dependent regulation of N-methyl-D-aspartate receptor subunit composition in the rat visual cortex during postnatal development. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 12876–12880. [[CrossRef](#)]
15. Quinlan, E.M.; Philpot, B.D.; Hugarir, R.L.; Bear, M.F. Rapid, experience-dependent expression of synaptic NMDA receptors in visual cortex in vivo. *Nat. Neurosci.* **1999**, *2*, 352–357. [[CrossRef](#)] [[PubMed](#)]
16. Sanz-Clemente, A.; Gray, J.A.; Ogilvie, K.A.; Nicoll, R.A.; Roche, K.W. Activated CaMKII couples GluN2B and casein kinase 2 to control synaptic NMDA receptors. *Cell Rep.* **2013**, *3*, 607–614. [[CrossRef](#)] [[PubMed](#)]
17. Sanz-Clemente, A.; Matta, J.A.; Isaac, J.T.; Roche, K.W. Casein kinase 2 regulates the NR2 subunit composition of synaptic NMDA receptors. *Neuron* **2010**, *67*, 984–996. [[CrossRef](#)]
18. Chen, B.S.; Gray, J.A.; Sanz-Clemente, A.; Wei, Z.; Thomas, E.V.; Nicoll, R.A.; Roche, K.W. SAP102 mediates synaptic clearance of NMDA receptors. *Cell Rep.* **2012**, *2*, 1120–1128. [[CrossRef](#)]
19. Halt, A.R.; Dallapiazza, R.F.; Zhou, Y.; Stein, I.S.; Qian, H.; Juntti, S.; Wojcik, S.; Brose, N.; Silva, A.J.; Hell, J.W. CaMKII binding to GluN2B is critical during memory consolidation. *EMBO J.* **2012**, *31*, 1203–1216. [[CrossRef](#)]
20. McKay, S.; Ryan, T.J.; McQueen, J.; Indersmitten, T.; Marwick, K.F.M.; Hasel, P.; Kopanitsa, M.V.; Baxter, P.S.; Martel, M.A.; Kind, P.C.; et al. The Developmental Shift of NMDA Receptor Composition Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences. *Cell Rep.* **2018**, *25*, 841–851.e844. [[CrossRef](#)]
21. Mota Vieira, M.; Nguyen, T.A.; Wu, K.; Badger, J.D., 2nd; Collins, B.M.; Anggono, V.; Lu, W.; Roche, K.W. An Epilepsy-Associated GRIN2A Rare Variant Disrupts CaMKIIalpha Phosphorylation of GluN2A and NMDA Receptor Trafficking. *Cell Rep.* **2020**, *32*, 108104. [[CrossRef](#)] [[PubMed](#)]
22. Yong, X.L.H.; Zhang, L.; Yang, L.; Chen, X.; Tan, J.Z.A.; Yu, X.; Chandra, M.; Livingstone, E.; Widagdo, J.; Vieira, M.M.; et al. Regulation of NMDA receptor trafficking and gating by activity-dependent CaMKIIalpha phosphorylation of the GluN2A subunit. *Cell Rep.* **2021**, *36*, 109338. [[CrossRef](#)]
23. Frank, R.A.; Komiyama, N.H.; Ryan, T.J.; Zhu, F.; O'Dell, T.J.; Grant, S.G. NMDA receptors are selectively partitioned into complexes and supercomplexes during synapse maturation. *Nat. Commun.* **2016**, *7*, 11264. [[CrossRef](#)] [[PubMed](#)]
24. Edman, S.; McKay, S.; Macdonald, L.J.; Samadi, M.; Livesey, M.R.; Hardingham, G.E.; Wyllie, D.J. TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner. *Neuropharmacology* **2012**, *63*, 441–449. [[CrossRef](#)] [[PubMed](#)]
25. McKay, S.; Griffiths, N.H.; Butters, P.A.; Thubron, E.B.; Hardingham, G.E.; Wyllie, D.J. Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. *Br. J. Pharm.* **2012**, *166*, 924–937. [[CrossRef](#)] [[PubMed](#)]
26. Stroebel, D.; Casado, M.; Paoletti, P. Triheteromeric NMDA receptors: From structure to synaptic physiology. *Curr. Opin. Physiol.* **2018**, *2*, 1–12. [[CrossRef](#)]
27. Hoffmann, H.; Gremme, T.; Hatt, H.; Gottmann, K. Synaptic activity-dependent developmental regulation of NMDA receptor subunit expression in cultured neocortical neurons. *J. Neurochem.* **2000**, *75*, 1590–1599. [[CrossRef](#)]
28. Ishchenko, Y.; Carrizales, M.G.; Koleske, A.J. Regulation of the NMDA receptor by its cytoplasmic domains: (How) is the tail wagging the dog? *Neuropharmacology* **2021**, *195*, 108634. [[CrossRef](#)] [[PubMed](#)]
29. Bramswig, N.C.; Ludecke, H.J.; Alanay, Y.; Albrecht, B.; Barthelmie, A.; Boduroglu, K.; Braunholz, D.; Caliebe, A.; Chrzanowska, K.H.; Czeschik, J.C.; et al. Exome sequencing unravels unexpected differential diagnoses in individuals with the tentative diagnosis of Coffin-Siris and Nicolaides-Baraitser syndromes. *Hum. Genet.* **2015**, *134*, 553–568. [[CrossRef](#)]
30. Chen, W.; Shieh, C.; Swanger, S.A.; Tankovic, A.; Au, M.; McGuire, M.; Tagliati, M.; Graham, J.M.; Madan-Khetarpal, S.; Traynelis, S.F.; et al. GRIN1 mutation associated with intellectual disability alters NMDA receptor trafficking and function. *J. Hum. Genet.* **2017**, *62*, 589–597. [[CrossRef](#)]

31. Dimassi, S.; Labalme, A.; Lesca, G.; Rudolf, G.; Bruneau, N.; Hirsch, E.; Arzimanoglou, A.; Motte, J.; de Saint Martin, A.; Boutry-Kryza, N.; et al. A subset of genomic alterations detected in rolandic epilepsies contains candidate or known epilepsy genes including GRIN2A and PRRT2. *Epilepsia* **2014**, *55*, 370–378. [[CrossRef](#)]
32. Endele, S.; Rosenberger, G.; Geider, K.; Popp, B.; Tamer, C.; Stefanova, I.; Milh, M.; Kortum, F.; Fritsch, A.; Pientka, F.K.; et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. *Nat. Genet.* **2010**, *42*, 1021–1026. [[CrossRef](#)]
33. Firth, H.V.; Richards, S.M.; Bevan, A.P.; Clayton, S.; Corpas, M.; Rajan, D.; Van Vooren, S.; Moreau, Y.; Pettett, R.M.; Carter, N.P. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. *Am. J. Hum. Genet.* **2009**, *84*, 524–533. [[CrossRef](#)]
34. Freunschtl, I.; Popp, B.; Blank, R.; Endele, S.; Moog, U.; Petri, H.; Prott, E.C.; Reis, A.; Rubo, J.; Zabel, B.; et al. Behavioral phenotype in five individuals with de novo mutations within the GRIN2B gene. *Behav. Brain Funct.* **2013**, *9*, 20. [[CrossRef](#)]
35. Grozeva, D.; Carss, K.; Spasic-Boskovic, O.; Tejada, M.I.; Gecz, J.; Shaw, M.; Corbett, M.; Haan, E.; Thompson, E.; Friend, K.; et al. Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability. *Hum. Mutat.* **2015**, *36*, 1197–1204. [[CrossRef](#)]
36. Lal, D.; Steinbrucker, S.; Schubert, J.; Sander, T.; Becker, F.; Weber, Y.; Lerche, H.; Thiele, H.; Krause, R.; Lehesjoki, A.E.; et al. Investigation of GRIN2A in common epilepsy phenotypes. *Epilepsy Res.* **2015**, *115*, 95–99. [[CrossRef](#)]
37. Lemke, J.R.; Hendrickx, R.; Geider, K.; Laube, B.; Schwake, M.; Harvey, R.J.; James, V.M.; Pepler, A.; Steiner, I.; Hortnagel, K.; et al. GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy. *Ann. Neurol.* **2014**, *75*, 147–154. [[CrossRef](#)]
38. Lemke, J.R.; Lal, D.; Reinthaler, E.M.; Steiner, I.; Nothnagel, M.; Alber, M.; Geider, K.; Laube, B.; Schwake, M.; Finsterwalder, K.; et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. *Nat. Genet.* **2013**, *45*, 1067–1072. [[CrossRef](#)]
39. Lesca, G.; Rudolf, G.; Bruneau, N.; Lozovaya, N.; Labalme, A.; Boutry-Kryza, N.; Salmi, M.; Tsintsadze, T.; Addis, L.; Motte, J.; et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. *Nat. Genet.* **2013**, *45*, 1061–1066. [[CrossRef](#)]
40. Li, Q.Q.; Chen, J.; Hu, P.; Jia, M.; Sun, J.H.; Feng, H.Y.; Qiao, F.C.; Zang, Y.Y.; Shi, Y.Y.; Chen, G.; et al. Enhancing GluN2A-type NMDA receptors impairs long-term synaptic plasticity and learning and memory. *Mol. Psychiatry* **2022**. [[CrossRef](#)]
41. Liu, S.; Zhou, L.; Yuan, H.; Vieira, M.; Sanz-Clemente, A.; Badger, J.D., 2nd; Lu, W.; Traynelis, S.F.; Roche, K.W. A Rare Variant Identified Within the GluN2B C-Terminus in a Patient with Autism Affects NMDA Receptor Surface Expression and Spine Density. *J. Neurosci.* **2017**, *37*, 4093–4102. [[CrossRef](#)] [[PubMed](#)]
42. Myers, R.A.; Casals, F.; Gauthier, J.; Hamdan, F.F.; Keebler, J.; Boyko, A.R.; Bustamante, C.D.; Piton, A.M.; Spiegelman, D.; Henrion, E.; et al. A population genetic approach to mapping neurological disorder genes using deep resequencing. *PLoS Genet.* **2011**, *7*, e1001318. [[CrossRef](#)] [[PubMed](#)]
43. O’Roak, B.J.; Vives, L.; Fu, W.; Egertson, J.D.; Stanaway, I.B.; Phelps, I.G.; Carvill, G.; Kumar, A.; Lee, C.; Ankenman, K.; et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science* **2012**, *338*, 1619–1622. [[CrossRef](#)]
44. Pan, Y.; Chen, J.; Guo, H.; Ou, J.; Peng, Y.; Liu, Q.; Shen, Y.; Shi, L.; Liu, Y.; Xiong, Z.; et al. Association of genetic variants of GRIN2B with autism. *Sci. Rep.* **2015**, *5*, 8296. [[CrossRef](#)] [[PubMed](#)]
45. Platzner, K.; Yuan, H.; Schutz, H.; Winschel, A.; Chen, W.; Hu, C.; Kusumoto, H.; Heyne, H.O.; Helbig, K.L.; Tang, S.; et al. GRIN2B encephalopathy: Novel findings on phenotype, variant clustering, functional consequences and treatment aspects. *J. Med. Genet.* **2017**, *54*, 460–470. [[CrossRef](#)]
46. Rauch, A.; Wiczorek, D.; Graf, E.; Wieland, T.; Endele, S.; Schwarzmayr, T.; Albrecht, B.; Bartholdi, D.; Beygo, J.; Di Donato, N.; et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: An exome sequencing study. *Lancet* **2012**, *380*, 1674–1682. [[CrossRef](#)]
47. Stessman, H.A.; Xiong, B.; Coe, B.P.; Wang, T.; Hoekzema, K.; Fenckova, M.; Kvarnung, M.; Gerdtts, J.; Trinh, S.; Cosemans, N.; et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. *Nat. Genet.* **2017**, *49*, 515–526. [[CrossRef](#)]
48. Takasaki, Y.; Koide, T.; Wang, C.; Kimura, H.; Xing, J.; Kushima, I.; Ishizuka, K.; Mori, D.; Sekiguchi, M.; Ikeda, M.; et al. Mutation screening of GRIN2B in schizophrenia and autism spectrum disorder in a Japanese population. *Sci. Rep.* **2016**, *6*, 33311. [[CrossRef](#)]
49. Tarabeux, J.; Kebir, O.; Gauthier, J.; Hamdan, F.F.; Xiong, L.; Piton, A.; Spiegelman, D.; Henrion, E.; Millet, B.; S2D team; et al. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. *Transl. Psychiatry* **2011**, *1*, e55. [[CrossRef](#)]
50. Venkateswaran, S.; Myers, K.A.; Smith, A.C.; Beaulieu, C.L.; Schwartzentruber, J.A.; Consortium, F.C.; Majewski, J.; Bulman, D.; Boycott, K.M.; Dymont, D.A. Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel, de novo GRIN2A mutation. *Epilepsia* **2014**, *55*, e75–e79. [[CrossRef](#)]
51. Von Stulpnagel, C.; Ensslen, M.; Moller, R.S.; Pal, D.K.; Masnada, S.; Veggiotti, P.; Piazza, E.; Dreesmann, M.; Hartlieb, T.; Herberhold, T.; et al. Epilepsy in patients with GRIN2A alterations: Genetics, neurodevelopment, epileptic phenotype and response to anticonvulsive drugs. *Eur. J. Paediatr. Neurol.* **2017**, *21*, 530–541. [[CrossRef](#)] [[PubMed](#)]
52. Williams, H.J.; Georgieva, L.; Dwyer, S.; Kirov, G.; Owen, M.J.; O’Donovan, M.C. Absence of de novo point mutations in exons of GRIN2B in a large schizophrenia trio sample. *Schizophr. Res.* **2012**, *141*, 274–276. [[CrossRef](#)] [[PubMed](#)]

53. Keith, R.E.; Azcarate, J.M.; Keith, M.J.; Hung, C.W.; Badakhsh, M.F.; Dumas, T.C. Direct Intracellular Signaling by the Carboxy terminus of NMDA Receptor GluN2 Subunits Regulates Dendritic Morphology in Hippocampal CA1 Pyramidal Neurons. *Neuroscience* **2019**, *396*, 138–153. [[CrossRef](#)] [[PubMed](#)]
54. Addis, L.; Virdee, J.K.; Vidler, L.R.; Collier, D.A.; Pal, D.K.; Ursu, D. Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency—Molecular profiling and functional rescue. *Sci. Rep.* **2017**, *7*, 66. [[CrossRef](#)]
55. Cooper, L.N.; Bear, M.F. The BCM theory of synapse modification at 30: Interaction of theory with experiment. *Nat. Rev. Neurosci.* **2012**, *13*, 798–810. [[CrossRef](#)]
56. Smith, G.B.; Heynen, A.J.; Bear, M.F. Bidirectional synaptic mechanisms of ocular dominance plasticity in visual cortex. *Philos. Trans. R Soc. Lond. B Biol. Sci.* **2009**, *364*, 357–367. [[CrossRef](#)]
57. Hanson, J.E.; Ma, K.; Elstrott, J.; Weber, M.; Saillet, S.; Khan, A.S.; Simms, J.; Liu, B.; Kim, T.A.; Yu, G.Q.; et al. GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer’s Disease Models. *Cell Rep.* **2020**, *30*, 381–396.e384. [[CrossRef](#)]
58. Acutain, M.F.; Griebler Luft, J.; Vazquez, C.A.; Popik, B.; Cercato, M.C.; Epstein, A.; Salvetti, A.; Jerusalinsky, D.A.; de Oliveira Alvares, L.; Baez, M.V. Reduced Expression of Hippocampal GluN2A-NMDAR Increases Seizure Susceptibility and Causes Deficits in Contextual Memory. *Front. Neurosci.* **2021**, *15*, 644100. [[CrossRef](#)]
59. Gorlewicz, A.; Pijet, B.; Orlova, K.; Kaczmarek, L.; Knapska, E. Epileptiform GluN2B-driven excitation in hippocampus as a therapeutic target against temporal lobe epilepsy. *Exp. Neurol.* **2022**, *354*, 114087. [[CrossRef](#)]
60. Chen, B.; Feng, B.; Tang, Y.; You, Y.; Wang, Y.; Hou, W.; Hu, W.; Chen, Z. Blocking GluN2B subunits reverses the enhanced seizure susceptibility after prolonged febrile seizures with a wide therapeutic time-window. *Exp. Neurol.* **2016**, *283 Pt A*, 29–38. [[CrossRef](#)]
61. Mares, P.; Kozlova, L.; Mikulecka, A.; Kubova, H. The GluN2B-Selective Antagonist Ro 25-6981 Is Effective against PTZ-Induced Seizures and Safe for Further Development in Infantile Rats. *Pharmaceutics* **2021**, *13*, 1482. [[CrossRef](#)] [[PubMed](#)]
62. Tran, H.Q.; Chung, Y.H.; Shin, E.J.; Tran, T.V.; Jeong, J.H.; Jang, C.G.; Nah, S.Y.; Yamada, K.; Nabeshima, T.; Kim, H.C. MK-801, but not naloxone, attenuates high-dose dextromethorphan-induced convulsive behavior: Possible involvement of the GluN2B receptor. *Toxicol. Appl. Pharm.* **2017**, *334*, 158–166. [[CrossRef](#)] [[PubMed](#)]
63. Amador, A.; Bostick, C.D.; Olson, H.; Peters, J.; Camp, C.R.; Krizay, D.; Chen, W.; Han, W.; Tang, W.; Kanber, A.; et al. Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. *Brain* **2020**, *143*, 2039–2057. [[CrossRef](#)]
64. Benke, T.A.; Park, K.; Krey, I.; Camp, C.R.; Song, R.; Ramsey, A.J.; Yuan, H.; Traynelis, S.F.; Lemke, J. Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs. *Neuropharmacology* **2021**, *199*, 108805. [[CrossRef](#)] [[PubMed](#)]
65. Epi, P.M.C. A roadmap for precision medicine in the epilepsies. *Lancet Neurol.* **2015**, *14*, 1219–1228.
66. Han, W.; Yuan, H.; Allen, J.P.; Kim, S.; Shaulsky, G.H.; Perszyk, R.E.; Traynelis, S.F.; Myers, S.J. Opportunities for Precision Treatment of GRIN2A and GRIN2B Gain-of-Function Variants in Triheteromeric N-Methyl-D-Aspartate Receptors. *J. Pharm. Exp. Ther.* **2022**, *381*, 54–66. [[CrossRef](#)] [[PubMed](#)]
67. Strehlow, V.; Rieubland, C.; Gallati, S.; Kim, S.; Myers, S.J.; Peterson, V.; Ramsey, A.J.; Teuscher, D.D.; Traynelis, S.F.; Lemke, J.R. Compound-heterozygous GRIN2A null variants associated with severe developmental and epileptic encephalopathy. *Epilepsia* **2022**, 1–6. [[CrossRef](#)]
68. Sapkota, K.; Dore, K.; Tang, K.; Irvine, M.; Fang, G.; Burnell, E.S.; Malinow, R.; Jane, D.E.; Monaghan, D.T. The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators. *Biochem. Pharm.* **2019**, *159*, 140–153. [[CrossRef](#)]
69. Olney, J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. *Science* **1969**, *164*, 719–721. [[CrossRef](#)]
70. Choi, D.W. Ionic dependence of glutamate neurotoxicity. *J. Neurosci.* **1987**, *7*, 369–379. [[CrossRef](#)]
71. Tymianski, M.; Charlton, M.P.; Carlen, P.L.; Tator, C.H. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. *J. Neurosci.* **1993**, *13*, 2085–2104. [[CrossRef](#)] [[PubMed](#)]
72. Sattler, R.; Charlton, M.P.; Hafner, M.; Tymianski, M. Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. *J. Neurochem.* **1998**, *71*, 2349–2364. [[CrossRef](#)] [[PubMed](#)]
73. Hardingham, G.E.; Bading, H. The Yin and Yang of NMDA receptor signalling. *Trends Neurosci.* **2003**, *26*, 81–89. [[CrossRef](#)]
74. Lipton, S.A.; Kater, S.B. Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. *Trends Neurosci.* **1989**, *12*, 265–270. [[CrossRef](#)]
75. Weilingner, N.L.; Lohman, A.W.; Rakai, B.D.; Ma, E.M.; Bialecki, J.; Masliewska, V.; Rilea, T.; Bandet, M.V.; Ikuta, N.T.; Scott, L.; et al. Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity. *Nat. Neurosci.* **2016**, *19*, 432–442.
76. Chen, M.; Lu, T.J.; Chen, X.J.; Zhou, Y.; Chen, Q.; Feng, X.Y.; Xu, L.; Duan, W.H.; Xiong, Z.Q. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. *Stroke* **2008**, *39*, 3042–3048. [[CrossRef](#)]
77. Zheng, M.; Liao, M.; Cui, T.; Tian, H.; Fan, D.S.; Wan, Q. Regulation of nuclear TDP-43 by NR2A-containing NMDA receptors and PTEN. *J. Cell Sci.* **2012**, *125 Pt 6*, 1556–1567. [[CrossRef](#)]
78. Hardingham, G.E.; Fukunaga, Y.; Bading, H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. *Nat. Neurosci.* **2002**, *5*, 405–414. [[CrossRef](#)]
79. Chang, N.; Li, L.; Hu, R.; Shan, Y.; Liu, B.; Li, L.; Wang, H.; Feng, H.; Wang, D.; Cheung, C.; et al. Differential regulation of NMDA receptor function by DJ-1 and PINK1. *Aging Cell* **2010**, *9*, 837–850. [[CrossRef](#)]

80. Bell, K.F.; Hardingham, G.E. The influence of synaptic activity on neuronal health. *Curr. Opin. Neurobiol.* **2011**, *21*, 299–305. [[CrossRef](#)]
81. Hagenston, A.M.; Bading, H. Calcium signaling in synapse-to-nucleus communication. *Cold Spring Harb. Perspect. Biol.* **2011**, *3*, a004564. [[CrossRef](#)] [[PubMed](#)]
82. Hardingham, G.E.; Bading, H. Nuclear calcium: A key regulator of gene expression. *Biometals* **1998**, *11*, 345–358. [[CrossRef](#)]
83. McKenzie, G.J.; Stevenson, P.; Ward, G.; Papadia, S.; Bading, H.; Chawla, S.; Privalsky, M.; Hardingham, G.E. Nuclear Ca²⁺ and CaM kinase IV specify hormonal- and Notch-responsiveness. *J. Neurochem.* **2005**, *93*, 171–185. [[CrossRef](#)] [[PubMed](#)]
84. Soriano, F.X.; Hardingham, G.E. Compartmentalized NMDA receptor signalling to survival and death. *J. Physiol.* **2007**, *584*, 381–387. [[CrossRef](#)]
85. Wahl, A.S.; Buchthal, B.; Rode, F.; Bomholt, S.F.; Freitag, H.E.; Hardingham, G.E.; Ronn, L.C.; Bading, H. Hypoxic/ischemic conditions induce expression of the putative pro-death gene *Clca1* via activation of extrasynaptic N-methyl-D-aspartate receptors. *Neuroscience* **2009**, *158*, 344–352. [[CrossRef](#)] [[PubMed](#)]
86. Martel, M.A.; Wyllie, D.J.; Hardingham, G.E. In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. *Neuroscience* **2009**, *158*, 334–343. [[CrossRef](#)] [[PubMed](#)]
87. Papadia, S.; Soriano, F.X.; Leveille, F.; Martel, M.A.; Dakin, K.A.; Hansen, H.H.; Kaindl, A.; Sifringer, M.; Fowler, J.; Stefovskaja, V.; et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. *Nat. Neurosci.* **2008**, *11*, 476–487. [[CrossRef](#)]
88. Gupta, K.; Hardingham, G.E.; Chandran, S. NMDA receptor-dependent glutamate excitotoxicity in human embryonic stem cell-derived neurons. *Neurosci. Lett.* **2013**, *543*, 95–100. [[CrossRef](#)]
89. Puddifoot, C.; Martel, M.A.; Soriano, F.X.; Camacho, A.; Vidal-Puig, A.; Wyllie, D.J.; Hardingham, G.E. PGC-1 α negatively regulates extrasynaptic NMDAR activity and excitotoxicity. *J. Neurosci.* **2012**, *32*, 6995–7000. [[CrossRef](#)]
90. Martel, M.A.; Ryan, T.J.; Bell, K.F.; Fowler, J.H.; McMahan, A.; Al-Mubarak, B.; Komiyama, N.H.; Horsburgh, K.; Kind, P.C.; Grant, S.G.; et al. The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. *Neuron* **2012**, *74*, 543–556. [[CrossRef](#)]
91. Aarts, M.; Liu, Y.; Liu, L.; Besshoh, S.; Arundine, M.; Gurd, J.W.; Wang, Y.T.; Salter, M.W.; Tymianski, M. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. *Science* **2002**, *298*, 846–850. [[CrossRef](#)] [[PubMed](#)]
92. Park, C.; Shin, K.S.; Ryu, J.H.; Kang, K.; Kim, J.; Ahn, H.; Huh, Y. The inhibition of nitric oxide synthase enhances PSA-NCAM expression and CREB phosphorylation in the rat hippocampus. *Neuroreport* **2004**, *15*, 231–234. [[CrossRef](#)]
93. Zhu, X.J.; Hua, Y.; Jiang, J.; Zhou, Q.G.; Luo, C.X.; Han, X.; Lu, Y.M.; Zhu, D.Y. Neuronal nitric oxide synthase-derived nitric oxide inhibits neurogenesis in the adult dentate gyrus by down-regulating cyclic AMP response element binding protein phosphorylation. *Neuroscience* **2006**, *141*, 827–836. [[CrossRef](#)] [[PubMed](#)]
94. Muir, K.W. Glutamate-based therapeutic approaches: Clinical trials with NMDA antagonists. *Curr. Opin. Pharm.* **2006**, *6*, 53–60. [[CrossRef](#)] [[PubMed](#)]
95. Cook, D.J.; Teves, L.; Tymianski, M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. *Nature* **2012**, *483*, 213–217. [[CrossRef](#)] [[PubMed](#)]
96. Hill, M.D.; Goyal, M.; Menon, B.K.; Nogueira, R.G.; McTaggart, R.A.; Demchuk, A.M.; Poppe, A.Y.; Buck, B.H.; Field, T.S.; Dowlatshahi, D.; et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): A multicentre, double-blind, randomised controlled trial. *Lancet* **2020**, *395*, 878–887. [[CrossRef](#)]
97. Marko, M.; Cimflova, P.; Poppe, A.Y.; Kashani, N.; Singh, N.; Ospel, J.; Mayank, A.; van Adel, B.; McTaggart, R.A.; Nogueira, R.G.; et al. Management and outcome of patients with acute ischemic stroke and tandem carotid occlusion in the ESCAPE-NA1 trial. *J. Neurointerv. Surg.* **2022**, *14*, 429–433. [[CrossRef](#)]
98. Yan, J.; Bengtson, C.P.; Buchthal, B.; Hagenston, A.M.; Bading, H. Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants. *Science* **2020**, *370*, eaay3302. [[CrossRef](#)]
99. Zong, P.; Feng, J.; Yue, Z.; Li, Y.; Wu, G.; Sun, B.; He, Y.; Miller, B.; Yu, A.S.; Su, Z.; et al. Functional coupling of TRPM2 and extrasynaptic NMDARs exacerbates excitotoxicity in ischemic brain injury. *Neuron* **2022**, *110*, 1944–1958.e1948. [[CrossRef](#)]
100. Alim, I.; Teves, L.; Li, R.; Mori, Y.; Tymianski, M. Modulation of NMDAR subunit expression by TRPM2 channels regulates neuronal vulnerability to ischemic cell death. *J. Neurosci.* **2013**, *33*, 17264–17277. [[CrossRef](#)]
101. Lan, J.Y.; Skeberdis, V.A.; Jover, T.; Grooms, S.Y.; Lin, Y.; Araneda, R.C.; Zheng, X.; Bennett, M.V.; Zukin, R.S. Protein kinase C modulates NMDA receptor trafficking and gating. *Nat. Neurosci.* **2001**, *4*, 382–390. [[CrossRef](#)]
102. Zheng, X.; Zhang, L.; Wang, A.P.; Bennett, M.V.; Zukin, R.S. Protein kinase C potentiation of N-methyl-D-aspartate receptor activity is not mediated by phosphorylation of N-methyl-D-aspartate receptor subunits. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 15262–15267. [[CrossRef](#)] [[PubMed](#)]
103. Tu, W.; Xu, X.; Peng, L.; Zhong, X.; Zhang, W.; Soundarapandian, M.M.; Balel, C.; Wang, M.; Jia, N.; Zhang, W.; et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. *Cell* **2010**, *140*, 222–234. [[CrossRef](#)] [[PubMed](#)]
104. McQueen, J.; Ryan, T.J.; McKay, S.; Marwick, K.; Baxter, P.; Carpanini, S.M.; Wishart, T.M.; Gillingwater, T.H.; Manson, J.C.; Wyllie, D.J.A.; et al. Pro-death NMDA receptor signaling is promoted by the GluN2B C-terminus independently of Dapk1. *Elife* **2017**, *6*, e17161. [[CrossRef](#)]

105. Tullis, J.E.; Buonarati, O.R.; Coultrap, S.J.; Bourke, A.M.; Tiemeier, E.L.; Kennedy, M.J.; Herson, P.S.; Bayer, K.U. GluN2B S1303 phosphorylation by CaMKII or DAPK1: No indication for involvement in ischemia or LTP. *iScience* **2021**, *24*, 103214. [[CrossRef](#)] [[PubMed](#)]
106. Buonarati, O.R.; Cook, S.G.; Goodell, D.J.; Chalmers, N.E.; Rumian, N.L.; Tullis, J.E.; Restrepo, S.; Coultrap, S.J.; Quillinan, N.; Herson, P.S.; et al. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. *Cell Rep.* **2020**, *30*, 1–8.e4. [[CrossRef](#)]
107. Marquez-Jurado, S.; Diaz-Colunga, J.; das Neves, R.P.; Martinez-Lorente, A.; Almazan, F.; Guantes, R.; Iborra, F.J. Mitochondrial levels determine variability in cell death by modulating apoptotic gene expression. *Nat. Commun.* **2018**, *9*, 389. [[CrossRef](#)]
108. Spencer, S.L.; Sorger, P.K. Measuring and modeling apoptosis in single cells. *Cell* **2011**, *144*, 926–939. [[CrossRef](#)]
109. Khan, Z.A.; Sumsuzzman, D.M.; Choi, J.; Hong, Y. Neurodegenerative effect of DAPK1 after cerebral hypoxia-ischemia is associated with its post-transcriptional and signal transduction regulations: A systematic review and meta-analysis. *Ageing Res. Rev.* **2022**, *76*, 101593. [[CrossRef](#)]
110. Lesept, F.; Chevilly, A.; Jezequel, J.; Ladepeche, L.; Macrez, R.; Aimable, M.; Lenoir, S.; Bertrand, T.; Rubrecht, L.; Galea, P.; et al. Tissue-type plasminogen activator controls neuronal death by raising surface dynamics of extrasynaptic NMDA receptors. *Cell Death Dis.* **2016**, *7*, e2466. [[CrossRef](#)]
111. Wu, F.; Echeverry, R.; Wu, J.; An, J.; Haile, W.B.; Cooper, D.S.; Catano, M.; Yepes, M. Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway. *Mol. Cell Neurosci.* **2013**, *52*, 9–19. [[CrossRef](#)] [[PubMed](#)]
112. Wu, F.; Wu, J.; Nicholson, A.D.; Echeverry, R.; Haile, W.B.; Catano, M.; An, J.; Lee, A.K.; Duong, D.; Dammer, E.B.; et al. Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. *J. Neurosci.* **2012**, *32*, 9848–9858. [[CrossRef](#)]
113. Harris, A.Z.; Pettit, D.L. Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. *J. Physiol.* **2007**, *584 Pt 2*, 509–519. [[CrossRef](#)] [[PubMed](#)]
114. Petralia, R.S.; Wang, Y.X.; Hua, F.; Yi, Z.; Zhou, A.; Ge, L.; Stephenson, F.A.; Wenthold, R.J. Organization of NMDA receptors at extrasynaptic locations. *Neuroscience* **2010**, *167*, 68–87. [[CrossRef](#)] [[PubMed](#)]
115. Thomas, C.G.; Miller, A.J.; Westbrook, G.L. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. *J. Neurophysiol.* **2006**, *95*, 1727–1734. [[CrossRef](#)] [[PubMed](#)]
116. Hedou, E.; Douceau, S.; Chevilly, A.; Varangot, A.; Thiebaut, A.M.; Triniac, H.; Bardou, I.; Ali, C.; Maillason, M.; Crepaldi, T.; et al. Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival. *Int. J. Mol. Sci.* **2021**, *22*, 13483. [[CrossRef](#)]
117. Fuller, S.; Steele, M.; Munch, G. Activated astroglia during chronic inflammation in Alzheimer’s disease—Do they neglect their neurosupportive roles? *Mutat. Res.* **2010**, *690*, 40–49. [[CrossRef](#)]
118. Ong, W.Y.; Tanaka, K.; Dawe, G.S.; Ittner, L.M.; Farooqui, A.A. Slow excitotoxicity in Alzheimer’s disease. *J. Alzheimers Dis.* **2013**, *35*, 643–668. [[CrossRef](#)]
119. Talantova, M.; Sanz-Blasco, S.; Zhang, X.; Xia, P.; Akhtar, M.W.; Okamoto, S.; Dziewczapolski, G.; Nakamura, T.; Cao, G.; Pratt, A.E.; et al. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, E2518–E2527. [[CrossRef](#)]
120. Bordji, K.; Becerril-Ortega, J.; Nicole, O.; Buisson, A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ss production. *J. Neurosci.* **2010**, *30*, 15927–15942. [[CrossRef](#)]
121. Hoey, S.E.; Williams, R.J.; Perkinson, M.S. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. *J. Neurosci.* **2009**, *29*, 4442–4460. [[CrossRef](#)] [[PubMed](#)]
122. Dore, K.; Aow, J.; Malinow, R. The Emergence of NMDA Receptor Metabotropic Function: Insights from Imaging. *Front. Synaptic Neurosci.* **2016**, *8*, 20. [[CrossRef](#)] [[PubMed](#)]
123. Aow, J.; Dore, K.; Malinow, R. Conformational signaling required for synaptic plasticity by the NMDA receptor complex. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 14711–14716. [[CrossRef](#)] [[PubMed](#)]
124. Dore, K.; Carrico, Z.; Alfonso, S.; Marino, M.; Koymans, K.; Kessels, H.W.; Malinow, R. PSD-95 protects synapses from beta-amyloid. *Cell Rep.* **2021**, *35*, 109194. [[CrossRef](#)]
125. Birnbaum, J.H.; Bali, J.; Rajendran, L.; Nitsch, R.M.; Tackenberg, C. Calcium flux-independent NMDA receptor activity is required for Abeta oligomer-induced synaptic loss. *Cell Death Dis.* **2015**, *6*, e1791. [[CrossRef](#)]
126. Kessels, H.W.; Nabavi, S.; Malinow, R. Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 4033–4038. [[CrossRef](#)]
127. Ittner, L.M.; Ke, Y.D.; Delerue, F.; Bi, M.; Gladbach, A.; van Eersel, J.; Wolfing, H.; Chieng, B.C.; Christie, M.J.; Napier, I.A.; et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. *Cell* **2010**, *142*, 387–397. [[CrossRef](#)]
128. Lalo, U.; Pankratov, Y.; Kirchhoff, F.; North, R.A.; Verkhratsky, A. NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. *J. Neurosci.* **2006**, *26*, 2673–2683. [[CrossRef](#)]
129. Schipke, C.G.; Ohlemeyer, C.; Matyash, M.; Nolte, C.; Kettenmann, H.; Kirchhoff, F. Astrocytes of the mouse neocortex express functional N-methyl-D-aspartate receptors. *FASEB J.* **2001**, *15*, 1270–1272. [[CrossRef](#)]

130. Alsaad, H.A.; DeKorver, N.W.; Mao, Z.; Dravid, S.M.; Arikath, J.; Monaghan, D.T. In the Telencephalon, GluN2C NMDA Receptor Subunit mRNA is Predominately Expressed in Glial Cells and GluN2D mRNA in Interneurons. *Neurochem. Res* **2019**, *44*, 61–77. [[CrossRef](#)]
131. Ravikrishnan, A.; Gandhi, P.J.; Shelkar, G.P.; Liu, J.; Pavuluri, R.; Dravid, S.M. Region-specific Expression of NMDA Receptor GluN2C Subunit in Parvalbumin-Positive Neurons and Astrocytes: Analysis of GluN2C Expression using a Novel Reporter Model. *Neuroscience* **2018**, *380*, 49–62. [[CrossRef](#)] [[PubMed](#)]
132. Yeung, J.H.Y.; Walby, J.L.; Palpagama, T.H.; Turner, C.; Waldvogel, H.J.; Faull, R.L.M.; Kwakowsky, A. Glutamatergic receptor expression changes in the Alzheimer's disease hippocampus and entorhinal cortex. *Brain Pathol.* **2021**, *31*, e13005. [[CrossRef](#)] [[PubMed](#)]
133. Jimenez-Blasco, D.; Santofimia-Castano, P.; Gonzalez, A.; Almeida, A.; Bolanos, J.P. Astrocyte NMDA receptors' activity sustains neuronal survival through a Cdk5-Nrf2 pathway. *Cell Death Differ.* **2015**, *22*, 1877–1889. [[CrossRef](#)] [[PubMed](#)]
134. Obara-Michlewska, M.; Ruskiewicz, J.; Zielinska, M.; Verkhatsky, A.; Albrecht, J. Astroglial NMDA receptors inhibit expression of Kir4.1 channels in glutamate-overexposed astrocytes in vitro and in the brain of rats with acute liver failure. *Neurochem. Int.* **2015**, *88*, 20–25. [[CrossRef](#)]
135. Skowronska, K.; Obara-Michlewska, M.; Czarnecka, A.; Dabrowska, K.; Zielinska, M.; Albrecht, J. Persistent Overexposure to N-Methyl-D-Aspartate (NMDA) Calcium-Dependently Downregulates Glutamine Synthetase, Aquaporin 4, and Kir4.1 Channel in Mouse Cortical Astrocytes. *Neurotox. Res.* **2019**, *35*, 271–280. [[CrossRef](#)]
136. Paille, V.; Picconi, B.; Bagetta, V.; Ghiglieri, V.; Sgobio, C.; Di Filippo, M.; Viscomi, M.T.; Giampa, C.; Fusco, F.R.; Gardoni, F.; et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. *J. Neurosci.* **2010**, *30*, 14182–14193. [[CrossRef](#)]
137. Gardoni, F.; Picconi, B.; Ghiglieri, V.; Polli, F.; Bagetta, V.; Bernardi, G.; Cattabeni, F.; Di Luca, M.; Calabresi, P. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. *J. Neurosci.* **2006**, *26*, 2914–2922. [[CrossRef](#)]
138. Ghasemzadeh, M.B.; Sharma, S.; Surmeier, D.J.; Eberwine, J.H.; Chesselet, M.F. Multiplicity of glutamate receptor subunits in single striatal neurons: An RNA amplification study. *Mol. Pharm.* **1996**, *49*, 852–859.
139. Landwehrmeyer, G.B.; Standaert, D.G.; Testa, C.M.; Penney, J.B., Jr.; Young, A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. *J. Neurosci.* **1995**, *15 Pt 2*, 5297–5307. [[CrossRef](#)]
140. Rigby, M.; Le Bourdelles, B.; Heavens, R.P.; Kelly, S.; Smith, D.; Butler, A.; Hammans, R.; Hills, R.; Xuereb, J.H.; Hill, R.G.; et al. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. *Neuroscience* **1996**, *73*, 429–447. [[CrossRef](#)]
141. Standaert, D.G.; Friberg, I.K.; Landwehrmeyer, G.B.; Young, A.B.; Penney, J.B., Jr. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. *Brain Res. Mol. Brain Res.* **1999**, *64*, 11–23. [[CrossRef](#)]
142. Fan, M.M.; Fernandes, H.B.; Zhang, L.Y.; Hayden, M.R.; Raymond, L.A. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. *J. Neurosci.* **2007**, *27*, 3768–3779. [[CrossRef](#)] [[PubMed](#)]
143. Milnerwood, A.J.; Gladding, C.M.; Pouladi, M.A.; Kaufman, A.M.; Hines, R.M.; Boyd, J.D.; Ko, R.W.; Vasuta, O.C.; Graham, R.K.; Hayden, M.R.; et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. *Neuron* **2010**, *65*, 178–190. [[CrossRef](#)] [[PubMed](#)]
144. Okamoto, S.; Pouladi, M.A.; Talantova, M.; Yao, D.; Xia, P.; Ehrnhoefer, D.E.; Zaidi, R.; Clemente, A.; Kaul, M.; Graham, R.K.; et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. *Nat. Med.* **2009**, *15*, 1407–1413. [[CrossRef](#)] [[PubMed](#)]
145. Javitt, D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. *Hillside J. Clin. Psychiatry* **1987**, *9*, 12–35.
146. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. *Am. J. Psychiatry* **1991**, *148*, 1301–1308.
147. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **2014**, *511*, 421–427. [[CrossRef](#)]
148. Ge, Y.; Chen, W.; Axerio-Cilies, P.; Wang, Y.T. NMDARs in Cell Survival and Death: Implications in Stroke Pathogenesis and Treatment. *Trends Mol. Med.* **2020**, *26*, 533–551. [[CrossRef](#)]
149. Bai, N.; Aida, T.; Yanagisawa, M.; Katou, S.; Sakimura, K.; Mishina, M.; Tanaka, K. NMDA receptor subunits have different roles in NMDA-induced neurotoxicity in the retina. *Mol. Brain* **2013**, *6*, 34. [[CrossRef](#)]
150. Bai, N.; Hayashi, H.; Aida, T.; Namekata, K.; Harada, T.; Mishina, M.; Tanaka, K. Dock3 interaction with a glutamate-receptor NR2D subunit protects neurons from excitotoxicity. *Mol. Brain* **2013**, *6*, 22. [[CrossRef](#)]
151. Jullienne, A.; Montagne, A.; Orset, C.; Lesept, F.; Jane, D.E.; Monaghan, D.T.; Maubert, E.; Vivien, D.; Ali, C. Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo. *Mol. Neurodegener.* **2011**, *6*, 68. [[CrossRef](#)] [[PubMed](#)]
152. Hubalkova, P.; Ladislav, M.; Vyklicky, V.; Smejkalova, T.; Hrcka Krausova, B.; Kysilov, B.; Krusek, J.; Naimova, Z.; Korinek, M.; Choudounska, H.; et al. Palmitoylation Controls NMDA Receptor Function and Steroid Sensitivity. *J. Neurosci.* **2021**, *41*, 2119–2134. [[CrossRef](#)] [[PubMed](#)]